NASDAQ:CARA

Cara Therapeutics (CARA) Stock Forecast, Price & News

$1.68

-0.11 (-6.15%)

(As of 02:52 PM ET)

Compare

Today's Range: $1.64
▼
$1.86
50-Day Range: $1.67
▼
$3.33
52-Week Range: $1.61
▼
$12.81

Volume: 557,285 shs
Average Volume: 903,242 shs
Market Capitalization: $90.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Cara Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 911.9% Upside
$17.00 Price Target
Short Interest: Healthy
4.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.39
Upright™ Environmental Score
News Sentiment: 0.55
Based on 3 Articles This Week
Insider Trading: Selling Shares
$13,222 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.93) to ($1.04) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

104th out of 963 stocks

Pharmaceutical Preparations Industry

33rd out of 451 stocks

3.3

Analyst's Opinion

Consensus Rating
Cara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Cara Therapeutics has a forecasted upside of 911.9% from its current price of $1.68.
Amount of Analyst Coverage
Cara Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.98% of the float of Cara Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cara Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cara Therapeutics has recently increased by 44.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cara Therapeutics does not currently pay a dividend.
Dividend Growth
Cara Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.
Environmental Sustainability
The Environmental Impact score for Cara Therapeutics is -1.39.

3.1

News and Social Media Coverage

News Sentiment
Cara Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for CARA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
4 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,222.00 in company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Cara Therapeutics is held by insiders.
Percentage Held by Institutions
68.04% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Cara Therapeutics are expected to grow in the coming year, from ($1.93) to ($1.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cara Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cara Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cara Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cara Therapeutics (NASDAQ:CARA) Stock

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

CARA Price History

30 days | 90 days | 365 days | Advanced Chart

CARA Stock News Headlines

September 25, 2023 | markets.businessinsider.com

Cara Therapeutics To Get $1.5 Mln Payment As KORSUVA IV Injection Syringe Approved In Japan

September 20, 2023 | americanbankingnews.com

Cara Therapeutics (NASDAQ:CARA) Share Price Passes Below Two Hundred Day Moving Average of $3.66

September 27, 2023 | Micro-Cap Stock Trader (Ad)

Windfall profits possible with this under-the-radar lithium stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 14, 2023 | finance.yahoo.com

Companies Like Cara Therapeutics (NASDAQ:CARA) Could Be Quite Risky

August 10, 2023 | finance.yahoo.com

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript

August 9, 2023 | msn.com

Piper Sandler Maintains Cara Therapeutics (CARA) Overweight Recommendation

August 8, 2023 | markets.businessinsider.com

6 Analysts Have This to Say About Cara Therapeutics

August 8, 2023 | finance.yahoo.com

Q2 2023 Cara Therapeutics Inc Earnings Call

September 27, 2023 | Micro-Cap Stock Trader (Ad)

Windfall profits possible with this under-the-radar lithium stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 8, 2023 | finance.yahoo.com

Cara Therapeutics Reports Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

July 24, 2023 | finance.yahoo.com

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

June 28, 2023 | msn.com

Stifel Reiterates Cara Therapeutics (CARA) Buy Recommendation

June 27, 2023 | msn.com

Jefferies Reiterates Cara Therapeutics (CARA) Buy Recommendation

June 27, 2023 | benzinga.com

Stifel Reiterates Buy on Cara Therapeutics, Maintains $28 Price Target

June 27, 2023 | msn.com

Jefferies says CMS extension for CARA dialysis drug should "unlock stock"

June 27, 2023 | benzinga.com

Jefferies Reiterates Buy on Cara Therapeutics, Maintains $18 Price Target

June 22, 2023 | msn.com

Bullish Thursday For Marijuana Stocks - Aurora Cannabis, Cara Therapeutics Among Top Gainers

June 14, 2023 | finance.yahoo.com

The past five years for Cara Therapeutics (NASDAQ:CARA) investors has not been profitable

June 6, 2023 | marketwatch.com

Several Stocks Touch 52-Week Lows After S&P Indices Moves

May 29, 2023 | benzinga.com

Pain Relief Therapeutics Market to Grow Significantly by 2029- Brandessence Market Research

May 25, 2023 | fool.com

Cara Therapeutics (NASDAQ: CARA)

May 25, 2023 | finance.yahoo.com

Cara Therapeutics, Inc.'s (NASDAQ:CARA) P/S Is On The Mark

May 18, 2023 | msn.com

UK drug pricing watchdog backs use of Cara, Vifor's Kapruvia in NHS

May 18, 2023 | finance.yahoo.com

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

May 16, 2023 | msn.com

B of A Securities Maintains Cara Therapeutics (CARA) Underperform Recommendation

May 16, 2023 | msn.com

HC Wainwright & Co. Maintains Cara Therapeutics (CARA) Buy Recommendation

See More Headlines

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Company Calendar

Last Earnings: 8/07/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CARA
CUSIP: N/A
CIK: 1346830
Web: www.caratherapeutics.com
Phone: (203) 406-3700
Fax: 203-567-1510
Employees: 106
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +918.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-85,470,000.00
Net Margins: -410.95%
Pretax Margin: -410.95%
Return on Equity: -75.82%
Return on Assets: -65.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.90
Quick Ratio: 4.77

Sales & Book Value

Annual Sales: $41.87 million
Price / Sales: 2.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.95 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 54,080,000
Free Float: 51,807,000
Market Cap: $90.31 million
Optionable: Optionable
Beta: 0.87

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Christopher A. Posner (Age 53)
Pres, CEO & Director
Comp: $1.2M

Mr. Ryan D. Maynard (Age 54)
Chief Financial Officer
Comp: $511.7k

Dr. Joana Goncalves M.D. (Age 49)
Chief Medical Officer
Comp: $747.25k

Dr. Derek T. Chalmers D.Sc. (Age 59)
Ph.D., Co-Founder & Sr. Advisor

Dr. Frédérique Menzaghi (Age 57)
Chief Scientific Officer and Sr. VP of R&D

Dr. Iris Francesconi Ph.D.
Chief Strategy Officer & Head of Investor Relations

Mr. Scott M. Terrillion (Age 60)
Chief Compliance Officer, Gen. Counsel & Corp. Sec.

Mr. Eric Vandal
Sr. VP of Commercial

Ms. Beth Weinberg R.Ph.
Sr. VP of Regulatory Affairs & QA

Mr. Matthew Murphy
Mang. of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CARA shares.
View CARA analyst ratings or view top-rated stocks.
What is Cara Therapeutics' stock price forecast for 2023?: 6 analysts have issued 12 month target prices for Cara Therapeutics' stock. Their CARA share price forecasts range from $4.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 918.0% from the stock's current price.
View analysts price targets for CARA or view top-rated stocks among Wall Street analysts.
How have CARA shares performed in 2023?: Cara Therapeutics' stock was trading at $10.74 at the beginning of the year. Since then, CARA stock has decreased by 84.5% and is now trading at $1.67.
View the best growth stocks for 2023 here.
Are investors shorting Cara Therapeutics?: Cara Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,240,000 shares, an increase of 44.5% from the August 31st total of 1,550,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 5.0% of the shares of the company are sold short.
View Cara Therapeutics' Short Interest.
When is Cara Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our CARA earnings forecast.
How were Cara Therapeutics' earnings last quarter?: Cara Therapeutics, Inc. (NASDAQ:CARA) announced its quarterly earnings data on Monday, August, 7th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.02. The biopharmaceutical company had revenue of $6.93 million for the quarter, compared to analyst estimates of $6.49 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 75.82% and a negative net margin of 410.95%.
What ETF holds Cara Therapeutics' stock ?: Amplify Seymour Cannabis ETF holds 161,542 shares of CARA stock, representing 1.93% of its portfolio.

What other stocks do shareholders of Cara Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).
What is Cara Therapeutics' stock symbol?: Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
Who are Cara Therapeutics' major shareholders?: Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.85%), Clearbridge Investments LLC (1.85%), Bain Capital Life Sciences Investors LLC (1.73%), Geode Capital Management LLC (1.73%), State Street Corp (1.70%) and Pinnacle Associates Ltd. (1.25%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends.
How do I buy shares of Cara Therapeutics?: Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cara Therapeutics' stock price today?: One share of CARA stock can currently be purchased for approximately $1.67.
How much money does Cara Therapeutics make?: Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $90.31 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.
How many employees does Cara Therapeutics have?: The company employs 106 workers across the globe.
How can I contact Cara Therapeutics?: Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial